CClinicalTrials.gg
Status unknownNCT03766568Sinus-EndoUpdated Jan 14, 2020

Single Use Device Endoscopy for the Diagnosis of Acute Bacterial Rhinosinusitis in Primary Care

An interventional study of JGG endoscope(R) in Acute Bacterial Sinusitis, sponsored by Dominik Glinz. Status unknown at 6 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-01-14.

Sponsored by Dominik Glinz · Not applicable, Interventional, and Diagnostic

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is a pilot study to assess the first time use of the JGG endoscope® in humans and in primary care. The JGG endoscope® is attached to a Heine® otoscope and allows to inspect and to collect samples from the middle meatus of the sinus. The JGG endoscope® is sterile packaged, for one way use and disposable.

Read the detailed description

Acute rhinosinusitis is one of the most common reasons for consultations and antibiotic prescriptions in primary care although the condition is primarily of viral origin. The main reason for antibiotic overuse in acute rhinosinusitis is the lack of diagnostic tests of sufficient accuracy to confirm or rule out the diagnosis of acute bacterial rhinosinusitis (ABRS).

The gold standard for the diagnosis of ABRS is a bacterial culture from sinus maxillary puncture. This procedure is painful, prone to complications and only done in selected patients by oto-rhino-laryngology (ORL) specialists or for research purposes. Therefore, endoscopy of the middle meatus and collection of diagnostic material from the ostium draining the sinus is the diagnostic method of choice for ABRS and routinely used by ORL specialists in house and elsewhere. In patients with clinical symptoms of sufficient severity and duration (typically 5-10 days) for ABRS, endoscopy has a sensitivity of 85.7% (95% confidence interval, 56.2-97.5), specificity of 90.6% (73.8-97.5), positive predictive value of 80% (51.4-94.7), negative predictive value of 93.5% (77.2-98.9) for culture proven ABRS when compared with cultures gained from sinus puncture. Because of high upfront costs and logistical reason (disinfection) endoscopy is not used in general practice or internal medicine.

Dr. Jens G. Hansen has developed the disposable JGG endoscope® (JGG stands for the surnames of the inventor and his wife) which can be attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.

In a pilot study the investigators would like to test the JGG endoscope® in 60 patients with suspected acute bacterial rhinosinusitis in the ORL unit of the University Hospital Basel and selected general practices that collaborate with the Centre for Primary Health Care of the University of Basel.

Objectives:

  1. To assess the feasibility of visualization and sample collection from the middle meatus with the JGG endoscope® in patients with clinically diagnosed acute bacterial rhinosinusitis in Swiss primary care setting
  2. to investigate whether the JGG endoscope® supports the decision of antibiotic prescribing
  3. to assess patients' and physicians' acceptability of the examination with the JGG endoscope®
  4. to investigate the prevalence of culture proven acute bacterial rhinosinusitis from samples of the middle meatus by the JGG endoscope® in patients with clinically diagnosed acute rhinosinusitis
  5. to investigate the number of patients with acute rhinosinusitis diagnosed by the JGG endoscope® with any and/or deferred antibiotic prescriptions
  6. to investigate the days with restrictions and symptoms in patients with acute rhinosinusitis with positive and negative bacterial cultures diagnosed by the JGG endoscope®
  7. to investigate any serious adverse event related to the JGG endoscope®.

Design Prospective observational cohort study (single arm study)

02

Conditions studied

  • Acute Bacterial Sinusitis

Keywords

  • Rhinosinusitis
  • upper respiratory tract infection
  • antibiotic
  • endoscopy
  • Otolaryngology
  • primary care
03

In context

Rhinosinusitis

330 studies on the registry are indexed under Rhinosinusitis; 55 are open to participants now.

This study's planned enrollment of 60 is close to the median of 60 across 227 interventional studies indexed under Rhinosinusitis.

Browse Rhinosinusitis studies →

Lead sponsor

This is the only study on the registry with Dominik Glinz as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults patients aged ≥18 years, with acute rhinosinusitis
  • Duration: worsening of symptoms after 5 days after onset of symptoms or if symptoms persist for more than 10 days, but no longer than 28 days. In addition, Criteria 1 and 2 must be fulfilled.

Criteria 1 for acute rhinosinusitis:

[Nasal blockage/obstruction/congestion OR Nasal Discharge (anterior/ posterior nasal drip)] AND [Facial pain/ pressure OR Reduction or loss of smell]

Criteria 2 for acute bacterial rhinosinusitis

Indicated by the presence of at least one of the following symptoms:

  • discoloured discharge (unilateral predominance)
  • severe local pain (unilateral predominance)
  • fever, that is >38°C
  • elevated inflammatory markers (CRP)
  • 'double sickening' whereby the patient's condition deteriorates.

Exclusion criteria

Exclusion Criteria:

  • Not being able to provide written informed consent in German (due to any mental or intellectual problem or other reasons)
  • Not being available for follow-up
  • Previous participation in Sinus-Endo study
  • Use of antibiotic the last 4 weeks
  • Known pathology or malformation of the sinuses or nasal cavity (like polyposis)
  • Known pregnancy
  • Allergic reactions to local anaesthetics
  • Anticoagulation therapy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Diagnostic with JGG endoscope

    Device: JGG endoscope(R)

Interventions

  • DeviceJGG endoscope(R)

    The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.

06

What researchers measure

Primary outcomes

  1. Prevalence of successful JGG endoscope® application

    The number of patients with successful visualization and sample collection from the middle meatus with the JGG endoscope®

    Time frame: Baseline Day 0

  2. Prevalence of complications

    The number of patients with complications related to the examination with the JGG endoscope®.

    Time frame: 2 weeks follow-up

Secondary outcomes

  1. Influence of JGG endoscope® to support the decision of antibiotic prescribing

    After each examination with the JGG endoscope, each physician will report on a Likert scale with five categories how the physician would judge usefulness of the device for decision to prescribe antibiotics.(The examination with the JGG endoscope(R) supported my decision whether to prescribe antibiotics or not; possible answers 1: don't agree, 2: partially don't agree, 3: neutral, 4: partially agree, 5: agree). The findings will be presented descriptively.

    Time frame: one weeks follow-up

  2. Prevalence of bacterial Rhinosinusitis

    The number of patient with culture proven acute bacterial rhinosinusitis from samples of the middle meatus diagnosed by the JGG endoscope®

    Time frame: 2 weeks follow-up

  3. Prevalence of any or deferred antibiotic prescriptions

    The number of patients with any or deferred antibiotic prescriptions in patients with acute rhinosinusitis diagnosed by the JGG endoscope®

    Time frame: 2 weeks follow-up

  4. Number of days with restrictions

    The mean days with restrictions and symptoms from acute rhinosinusitis at Day 14 in patients with positive and negative cultures as diagnosed with the JGG endoscope®

    Time frame: 2 weeks follow-up

  5. Patients's acceptability of JGG endoscope®

    The patients' acceptability of the device will be assessed on Likert scale (If I would suffer again from an akute sinusitis, I would again agree being investigated with the JGG endoscope(R); possible answers 1: don't agree, 2: partially don't agree, 3: don't know, 4: partially agree, 5: agree). The findings will be presented descriptively.

    Time frame: one week follow-up

  6. Physicians' acceptability by a global usefulness rating on Likert scales

    The physicians' acceptability will be evaluated by a global usefulness rating on Likert scales with five categories after recruitment completion (The ratio of additional effort due to the JGG endoscope(R) and the newly gained information is good, possible answers 1: don't agree, 2: partially don't agree, 3: neutral, 4: partially agree, 5: agree). The findings will be presented descriptively.

    Time frame: 6 month

  7. Prevalence of serious adverse events

    The number of patients with any serious adverse event within the two weeks follow-up

    Time frame: 2 weeks follow-up

07

Study locations

5 of 6 sites recruiting
  • Praxis Vogt
    Liestal, BL 4410, Switzerland
    • Jürg Vogt, MD · Contact · +619310080
    Recruiting
  • Hausarztpraxis Muttenz AG
    Muttenz, BL 4132, Switzerland
    • Bernhard Schaller, MD · Contact · +41614612828
    Recruiting
  • mediX toujours Pratteln
    Pratteln, BL 4133, Switzerland
    • Andreas Marti, MD · Contact · +41 61 825 90 90
    Recruiting
  • HNO Klinik, University Hospital Basel
    Basel, BS 4031, Switzerland
    • Katharina Leitmeyer, MD · Contact · +41 61 328 71 08
    Recruiting
  • mediX toujours Basel
    Basel, BS 4051, Switzerland
    • Caroline Trutmann, MD · Contact · +41 61 500 11 00
    Recruiting
  • Praxis Hammer
    Basel, BS 4057, Switzerland
    • Claus Diermayr, MD · Contact · +41 61 692 88 11
    Not yet recruiting
08

References and documents

Publications

  • Glinz D, Georg Hansen J, Trutmann C, Schaller B, Vogt J, Diermayr C, Marti A, Leitmeyer K, Doerig P, Zeller A, Welge-Luessen Lemcke A, Bucher HC. Single-use device endoscopy for the diagnosis of acute bacterial rhinosinusitis in primary care: A pilot and feasibility study. Clin Otolaryngol. 2021 Sep;46(5):1050-1056. doi: 10.1111/coa.13785. Epub 2021 May 24. PubMed 33866681 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 14, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03766568
Lead sponsor
Dominik Glinz
Collaborators
University Hospital, Basel, Switzerland
Responsible party
Dominik Glinz (Principal investigator, Basel Institute for Clinical Epidemiology and Biostatistics) — Sponsor-investigator
First posted
Dec 6, 2018
Start date
Dec 17, 2018
Primary completion
May 31, 2020 (estimated)
Completion
Sep 30, 2020 (estimated)
Last update
Jan 14, 2020

Study contacts

Dominik Glinz, Dr. sc.
Contact
dominik.glinz@usb.ch
+41 61 328 54 02
Heiner C Bucher, Prof.
Contact
heiner.bucher@usb.ch
+41 61 556 5100
Heiner C Bucher, Prof.
principal investigator · CEB

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion